Seurat Therapeutics

CO-FOUNDER AND EXECUTIVE CHAIRMAN

Dr. Sanders is a co-founder of Seurat Therapeutics. He serves as Executive Chairman of the Seurat Therapeutics Board of Directors of the company. He brings to Seurat Therapeutics extensive experience in biopharmaceutical product discovery, research and development, and company formation. He received his M.D. degree from the University of Chicago and trained in Internal Medicine at Barnes Hospital, Washington University Medical Center, in St. Louis. He completed fellowships in allergy, clinical immunology, and basic immunology research at the National Institute of Allergy and Infectious Diseases; and the National Cancer Institute. He trained in clinical rheumatology at the Johns Hopkins School of Medicine. He is certified by the American Board of Internal Medicine and holds dual sub-specialty board certifications in allergy/clinical immunology and rheumatology. Dr. Sanders held concurrent appointments in drug discovery and clinical pharmacology at the Upjohn Company from 1988 to 1990, and concurrent appointments as Director of Immunobiology Preclinical Research and Director of Clinical Immunology Research at Centocor, Inc., from 1990 to 1992. At Centocor, he was the medical director for the first clinical trials demonstrating the beneficial effects of a TNF inhibitor (Remicade) for the treatment of rheumatoid arthritis, and Crohn’s disease. Since 1992, Dr. Sanders has served as an advisor to more than 50 biopharmaceutical companies, in the areas of preclinical and clinical product development. He has participated in the design, execution, monitoring, or analysis of greater than 300 clinical trials; for more than 50 different drugs, biologics, gene therapies, and devices, across diverse therapeutic areas, including rheumatology, allergy, immunology, oncology, vaccines, and metabolic diseases. Dr. Sanders currently serves as a founding member of the advisory committee for the George Schultz Innovation Fund at the Polsky Center for Entrepreneurship and Innovation at the University of Chicago; and as a member of the Board of Trustees for the University of Rochester.

CO-FOUNDER, CHIEF SCIENTIFIC OFFICER

Richard Kraig is a board-certified neurologist and leads the Migraine Headache clinic at the University of Chicago. Dr. Kraig’s research centers on developing novel neurotherapeutics based on deciphering the immune signaling by which environmental enrichment (i.e., increased creativity and physical activity) improves brain health.

Dr. Kraig is also a professor in the Department of Neurology at The University of Chicago and the William D. Mabie Professor in the Neurosciences. He received his B.A. in Chemistry from Cornell College, his Ph.D. in Physiology and Biophysics from the University of Iowa, his M.D. from New York University, and completed his internship in Medicine at the University of Chicago as well as his residency in Neurology at the New York Hospital-Cornell Medical College.

EVP, Business Development, CFO

Ms. Lew has over 15 years of experience in business development, sales, marketing, and operations in global companies, and in early-stage start-up environments; including positions at Toshiba, ADAC Labs, Polymer Technology Group, DecisionView, Pano Logic, Ephox Corporation, Quantum3D, Inc., and Jasmine Networks, Inc. She has worked in multiple healthcare-related fields including nuclear medicine imaging equipment; radiation therapy planning systems; positron emission tomography, computerized tomography, and magnetic resonance imaging systems; clinical trial performance optimization software; and biomedical devices and components for cardiovascular, orthopedic and ophthalmic applications. She holds a Master of Science in Marketing from Golden Gate University and a Bachelor of Science in Business of Administration from San Francisco State University.

BOARD MEMBER

Scott Meadow is a private equity professional and faculty member of the University of Chicago Booth School of Business, where he is a clinical professor of entrepreneurship. He is the recipient of the Richard J. Daley Award. The Daley Medal acknowledges a single individual who has given direct and extraordinary support to the state of Illinois by participating in or being an advocate for the venture capital and private equity industry.

For nearly thirty years, Meadow has been a principal investor in the venture capital and private equity industry. He started his career at William Blair and Company, where he became a partner in 1983. He has been a General Partner at William Blair Venture Partners, Frontenac Company, the Sprout Group and is an associate partner at Edgewater Growth Capital Partners and founder of Maroon Partners, a consultancy enterprise focused on advising entrepreneurial and private equity endeavors and providing expert witness support in commercial disputes.

Throughout his career, he has approved hundreds of equity financings, and originated or created more than sixty investments including two dozen healthcare service companies.